🔺 What to do when markets are at an all-time high? Find smart bargains, like these.See Undervalued Stocks

Pluri Inc (PLUR)

Tel Aviv
Currency in ILS
1,955
+57(+3.00%)
Delayed Data
PLUR Scorecard
Full Analysis
Net income is expected to grow this year
Fair Value
Day's Range
1,8591,959
52 wk Range
1,5432,999
Key Statistics
Edit
Bid/Ask
1,866.00 / 1,955.00
Prev. Close
1,898
Open
1,959
Day's Range
1,859-1,959
52 wk Range
1,543-2,999
Volume
100
Average Volume (3m)
9.71K
1-Year Change
10.61%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PLUR Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash
Show more

Pluri Inc Company Profile

Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and cell-based technologies for various industries. It develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and a novel immunotherapy platform. The company’s product candidates include PLX-PAD, that is composed of maternal mesenchymal stromal cells originating from the placenta for the treatment of various indications, such as acute muscle injuries following hip fracture, acute respiratory distress syndrome due to COVID-19, peripheral artery disease, intermittent claudication, and critical limb ischemia; PLX-R18, is composed of fetal MSC like cells originating from the placenta for the treatment of hematopoietic complications of the H-ARS, and phase I trial to treat hematopoietic cell transplantation; and allogeneic MAIT cell therapy platform. It also offers cell manufacturing services; cell-based coffee; and develops and commercializes cultivated meat products. The company operates in the field of regenerative medicine, food-tech, CDMO, and agtech. It has collaboration agreement with Bar-Ilan University to advance cancer immunotherapy for solid tumors. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.

Compare PLUR to Peers and Sector

Metrics to compare
PLUR
Peers
Sector
Relationship
P/E Ratio
−1.3x−2.4x−0.6x
PEG Ratio
−0.05−0.030.00
Price/Book
−5.6x2.0x2.6x
Price / LTM Sales
49.1x44.3x3.2x
Upside (Analyst Target)
-277.0%46.2%
Fair Value Upside
Unlock6.9%7.0%Unlock

People Also Watch

186.44
NICE
-1.78%
20.09
OKLO
-8.31%
17.51
MBLY
+3.00%
365.34
MSTR
-7.51%

FAQ

What Is the Pluri Inc (PLUR) Stock Price Today?

The Pluri Inc stock price today is 1,955.00

What Stock Exchange Does Pluri Inc Trade On?

Pluri Inc is listed and trades on the Tel Aviv stock exchange.

What Is the Stock Symbol for Pluri Inc?

The stock symbol for Pluri Inc is "PLUR."

What Is the Pluri Inc Market Cap?

As of today, Pluri Inc market cap is 108.67M.

What is Pluri Inc Earnings Per Share?

The Pluri Inc EPS is -4.10.

From a Technical Analysis Perspective, Is PLUR a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.